Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. - Wikidata - wikimedia - TriplyDB

Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft.

Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft.

http://www.wikidata.org/entity/Q36920470

about

Patient-derived tumor xenografts: transforming clinical samples into mouse models Colorectal cancer models for novel drug discovery Predictive biomarkers in precision medicine and drug development against lung cancer Early phase clinical trials to identify optimal dosing and safety Pharmacogenetics and pharmacogenomics as tools in cancer therapy Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer.Patient-derived xenograft platform of OSCC: a renewable human bio-bank for preclinical cancer research and a new co-clinical model for treatment optimization.Patient-derived xenografts for individualized care in advanced sarcoma.Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions.Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment.First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma.Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes.Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.S100A4 in esophageal cancer: is this the one to blame?Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients.Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts.Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1.Drug sensitivity testing platforms for gastric cancer diagnostics.Chemo brain or tumor brain - that is the question: the presence of extracranial tumors profoundly affects molecular processes in the prefrontal cortex of TumorGraft mice.Patient-derived xenografts as tools in pharmaceutical development.Comparative mutational landscape analysis of patient-derived tumour xenografts.Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model.Primary human non-small cell lung and pancreatic tumorgraft models--utility and applications in drug discovery and tumor biology.Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer.Growth of malignant extracranial tumors alters microRNAome in the prefrontal cortex of TumorGraft mice.Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors.First-In-Human Phase 1 CRISPR Gene Editing Cancer Trials: Are We Ready?Targeting the Oncogenic Transcriptional Regulator MYB in Adenoid Cystic Carcinoma by Inhibition of IGF1R/AKT Signaling.Emerging Opportunities for Target Discovery in Rare Cancers.Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer.Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma.Preclinical mouse solid tumour models: status quo, challenges and perspectives.Growth of Malignant Non-CNS Tumors Alters Brain Metabolome.B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.Growth of Triple Negative and Progesterone Positive Breast Cancer Causes Oxidative Stress and Down-Regulates Neuroprotective Transcription Factor NPAS4 and NPAS4-Regulated Genes in Hippocampal Tissues of TumorGraft Mice-an Aging Connection.Protocol for the avatar acceptability study: a multiperspective cross-sectional study evaluating the acceptability of using patient-derived xenografts to guide personalised cancer care in Australia and New Zealand

P2860

Q24627425-22DEA0BD-6471-4775-B983-34F3D109ACC5 Q26795724-237DFE16-FE38-420F-89AF-62ADB8B5530E Q26824536-7E31C6FF-D66E-47BF-A94A-C7BEB27EED58 Q26865076-0E27B523-CA75-4590-A412-D894161619B2 Q28076200-331C8C58-01A2-4232-9C30-B76C792890F5 Q30423597-FDE4B18B-9902-4C12-8277-F9DFFD51C4D8 Q33457995-5BCC7075-E2D6-4A6C-851B-A9129CCFA2EC Q34413869-904FC092-8491-4046-B33E-6B1F9EE40170 Q34654508-52022B66-63B3-4304-85A0-CDEE4363627E Q34994030-78EAC6CD-C19C-4EB3-AA97-FEC84B7930C1 Q35067532-C06E98A7-1E15-427C-AEF2-DBF5C656F4B9 Q35110920-5173C0DB-5334-41D2-8084-DFE83E300149 Q35747414-1D99F841-DABC-427D-9039-F2774B2C0761 Q35760892-DAAF6BFD-6931-40CE-8C11-36E95F5AA23A Q36149312-58539F16-FA83-43DB-91D2-884784897B2E Q36166931-01A3FBD3-0E29-4A3B-BA44-67F7B1601196 Q36671291-DDA1B9E4-FCC8-479E-9068-E2467186E52A Q37269137-4ECCADD9-9A15-4CCD-92E9-333F62032CB1 Q37650703-E4A31891-587A-404D-BAF9-4B830EDB2580 Q38633116-DC83229B-FEE2-4993-9D9B-61ADC02A1E2B Q38649401-191AC148-F456-4F23-95D6-E30CF23F0A70 Q38732336-9FCD2DF9-394E-46FD-AF2C-5B8A86A8ECB1 Q40366394-6515E2DE-0D22-4EED-9248-CC712AB625F0 Q41915301-3545DF60-29F7-4558-89CC-C7AC7D46E6B4 Q43614648-73442C2E-EECC-44D0-BC61-1BDF950FD036 Q44636888-F958D61B-8711-4F48-BF3E-FA4FC2CCED9B Q44833373-CDE72A5F-1B10-4C0B-B3F0-D01091729CA5 Q45068320-2DD38C5D-5F2F-424F-AE4D-5269A210AA11 Q47283164-9FE3C8F9-FAF8-4DD2-8395-DAAAD9063145 Q47735648-AAE2AA91-CC88-4D45-BCAD-F46234E4752B Q47941750-AF321F98-C28B-4FB1-903D-F7668329BA14 Q48001140-2DD06BBF-9695-4DAF-9D44-CCE0F1CECFA2 Q49497626-C41D144F-17F7-4C39-9A8C-9D258C49DCCF Q50096902-7F2014B8-7014-496F-AD6F-B9B930F41EFD Q50420431-F39DDB18-35F0-4EDF-B1D5-01596E8F358C Q51441965-F7089E92-2C6A-4DE7-9461-D41F06624CD1 Q51761540-683408BF-C448-4F8F-83DD-4CA3F142C885 Q58795555-44A00562-6951-4B56-970C-9C32C5CF975B

P2860

Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft.

http://www.wikidata.org/entity/Q36920470

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Prioritizing phase I treatment ...... ng on personalized tumorgraft.

@en

type

label

Prioritizing phase I treatment ...... ng on personalized tumorgraft.

@en

prefLabel

Prioritizing phase I treatment ...... ng on personalized tumorgraft.

@en

P1433

Q36920470-8CAC6BEA-1BBE-4C70-938A-CE5FCAC38359

P1476

Q36920470-E2E1E6A3-77BE-4864-A157-8A2DCD1D5C67

P2093

Q36920470-193B4D28-3708-435F-9960-68BD98C71EFF

Q36920470-1F6BF9F6-41DD-4AFF-9DA6-E465E4E045FD

Q36920470-68354F17-EC9A-4C0A-A2C0-3BCA7A6AF551

Q36920470-73906F9A-A533-4C7A-A64E-145522331D85

Q36920470-8CC64874-438C-4AD5-9C00-353DAFDB2EE1

Q36920470-91494260-1BCB-4F67-B68F-080F5CCE262B

Q36920470-9CCD35A6-1E17-42A9-9AEA-1B45A84DECF6

Q36920470-ACDB1C52-C94E-40D1-B675-15AAABA0518B

Q36920470-F2B22BDF-90E6-4A80-8417-8C8396371C63

Q36920470-F99C349F-57A2-4304-BCA0-01A61F6E75DD

P2860

Q36920470-17C68394-E6E4-476B-A31C-8B49597A4885

Q36920470-3C7634AE-BD3D-4B35-ADBD-46F69372D124

Q36920470-6CB520E5-1BA2-4B2C-957E-84B4634230D2

Q36920470-7614C06A-E51B-477C-B1CE-9E417EF0D4EA

Q36920470-795A58C6-F0F0-4C95-8C2A-11A6568C1103

Q36920470-95020670-64EC-4173-A24C-14AEA8C997FC

Q36920470-A5E9FE91-3B44-442C-BF00-4FFBF4DE9CA0

Q36920470-A9DD6D3D-FB38-4E86-B36F-26FDE2A2DFF6

Q36920470-ADF75380-8EB8-4CF6-9BB5-1E54AE2D2FDE

Q36920470-FD1D96D7-0EC2-4291-8614-EE9BB60CC56E

P304

Q36920470-E1B1E50B-5490-4135-B561-F5E1AC649342

P31

Q36920470-DCB4B0BB-FA94-46CC-9CB7-008968AE41C0

P356

Q36920470-718A4058-F163-4AEC-A9EE-DF204D980DF1

P407

Q36920470-17C3A803-29C5-44C5-8E24-839118EE329B

P433

Q36920470-CFC305DB-FD7E-4C98-A032-6F4BD50EDC4F

P478

Q36920470-2CB01870-161C-4150-BA2B-9BBC8639F3FD

P577

Q36920470-9A011A0C-2F55-4594-8DE6-6537890D9344

P5875

Q36920470-F2E44900-C8B6-4627-A89B-47105948C498

P698

Q36920470-039B7FF7-8354-46AA-BC3A-7F98770711B1

P932

Q36920470-7F9AE660-F3C8-4F3B-9FA3-C89D6C328818

P356

JCO.2011.36.9678

P1433

Journal of Clinical Oncology

P1476

Prioritizing phase I treatment ...... ng on personalized tumorgraft.

@en

P2093

Antonio Calles-Blanco

http://www.w3.org/2001/XMLSchema#string

Belen-Rubio Viqueira

http://www.w3.org/2001/XMLSchema#string

David Sidransky

http://www.w3.org/2001/XMLSchema#string

Elizabeth Bruckheimer

http://www.w3.org/2001/XMLSchema#string

Emiliano Calvo

http://www.w3.org/2001/XMLSchema#string

Esther Ordoñez

http://www.w3.org/2001/XMLSchema#string

M Pia Morelli

http://www.w3.org/2001/XMLSchema#string

Manuel Hidalgo

http://www.w3.org/2001/XMLSchema#string

Michael J Wick

http://www.w3.org/2001/XMLSchema#string

Pedro P Lopez-Casas

http://www.w3.org/2001/XMLSchema#string

P2860

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.

Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review.

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.

Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group.

Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.

Distant metastasis in adenoid cystic carcinoma of salivary origin.

Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands

P304

e45-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.36.9678

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51902669

http://www.w3.org/2001/XMLSchema#string

P698

22184402

http://www.w3.org/2001/XMLSchema#string

P932

4874230

http://www.w3.org/2001/XMLSchema#string